SOPHiA GENETICS™

Distributed By : Genique Lifesciences

TISSUE BIOPSY

MSK-IMPACT® powered with SOPHiA DDM™

Break the boundaries of your comprehensive genomic profiling

Enhance your in-house comprehensive genomic profiling (CGP) research capabilities with MSK-IMPACT® powered with SOPHiA DDM™. Gain access to a decentralized version of a rigorously validated CGP assay, developed and used in routine by Memorial Sloan Kettering Cancer Center (MSK)[1].

Why choose MSK-IMPACT® powered with SOPHiA DDM™ for your CGP analysis?

Focus on what matters with expert knowledge-driven design

Benefit from best-in-class panel design of 505 key cancer-associated genes, meticulously **curated by MSK experts** and backed by >1000 publications from MSK investigators[a].

Identify the somatic origin of variants with certainty

Improve accuracy with a paired tumor FFPE and matched normal white blood cells approach, supporting detection of **tumor-specific variants** of somatic origin. Use **only 25% of your sequencing space** for the normal sample.

Easily distinguish between tumor-specific and germline variants

Unveil germline variants associated with cancer-risk, which may be missed by a tumor-only approach, and easily distinguish from somatic variants with intuitive results visualization.

Trust your results with robust analytical performance

Accurately detect SNVs/Indels (99.3% PPA), CNVs (95.2% PPA), MSI (99.4% OPA), and TMB (98.8% OPA) with proprietary AI agents that ensure **high analytical concordance** with MSK-IMPACT® used at MSK[2,b,c].

Increase efficiency with SOPHiA DDM™ and OncoPortal™ Knowledge Base

Go from **DNA to report in ~5 days** with a true end-to-end workflow that integrates user-friendly analysis, interpretation and reporting features, including access to MSK's Precision Oncology Knowledge Base, OncoKB™.

Interested in elevating your precision oncology program?
Contact us at info@sophiagenetics.com

MSK-IMPACT® powered with SOPHiA DDM™ is for research use only, not for use in diagnostic procedures.

[a]Publication figure relates to single-site test available at MSK only – accurate as of May 2025. [b]DNA fusions, TERT promoter, and MET exon skipping also detected. [c]Analytical assessment of RUO products.

[1]. MSK. MSK-IMPACT. Available at: https://www.mskcc.org/msk-impact. [2]. Pontis J, Mohammad F, Anjali A, et al. Poster 691. Presented at AACR Annual Meeting 2025, Chicago, IL, USA. CNVs, copy number variants; FFPE, formalin-fixed, paraffin-embedded; Indels, insertions and deletions; MSI, microsatellite instability; OPA, overall percent agreement; PPA, positive percent agreement; SNV, single nucleotide variants; TMB, tumor mutational burden.